Dr. Randy Mills, Ph.D., is President and CEO of Elutia Inc., as well as its cofounder. Dr. Mills is an internationally recognized expert in regenerative medicine who has led pioneering biotechnology organizations that have created more than $1 billion in shareholder value for investors. As CEO of Osiris Therapeutics (Nasdaq:OSIR), he commercialized five cell-therapy products responsible for $1.5 billion in sales and led the company through an IPO that increased shareholder value 41-fold. Osiris was eventually sold to Smith and Nephew for $660 million. Dr. Mills was also a co-founder and officer of Regeneration Technologies (Nasdaq:RTIX), where he led operations, R&D, regulatory and business development through its successful IPO. Dr. Mills holds a Ph.D. in Pharmaceutical Science and a B.S. in Microbiology from the University of Florida and completed an internship in Clinical Pathology at Shands Hospital at the University of Florida. Profile
Word count: 2,807
TWST: Thank you very much for joining us today. So to start things off, last September, Elutia changed its name from Aziyo Biologics. What was the rationale behind that
